高级检索
梁停停, 王文杰, 郝思远, 何光超, 徐云根. 小分子ERK抑制剂的研究进展[J]. 中国药科大学学报, 2020, 51(3): 260-269. DOI: 10.11665/j.issn.1000-5048.20200302
引用本文: 梁停停, 王文杰, 郝思远, 何光超, 徐云根. 小分子ERK抑制剂的研究进展[J]. 中国药科大学学报, 2020, 51(3): 260-269. DOI: 10.11665/j.issn.1000-5048.20200302
LIANG Tingting, WANG Wenjie, HE Guangchao, HE Guangchao, XU Yungen. Research progress of ERK small molecule inhibitors[J]. Journal of China Pharmaceutical University, 2020, 51(3): 260-269. DOI: 10.11665/j.issn.1000-5048.20200302
Citation: LIANG Tingting, WANG Wenjie, HE Guangchao, HE Guangchao, XU Yungen. Research progress of ERK small molecule inhibitors[J]. Journal of China Pharmaceutical University, 2020, 51(3): 260-269. DOI: 10.11665/j.issn.1000-5048.20200302

小分子ERK抑制剂的研究进展

Research progress of ERK small molecule inhibitors

  • 摘要: 细胞外信号调节激酶(ERK)是一种丝/苏氨酸蛋白激酶。作为RAS-RAF-MEK-ERK信号通路中关键的下游蛋白,其异常活化在肿瘤的发生发展中起着重要作用。选择性ERK1/2抑制剂能够阻断ERK信号通路,同时克服上游靶点突变而导致的耐药性。本文概述了MAPK信号通路的组成、ERK的结构与功能以及ERK信号通路在肿瘤发生发展中的作用,并重点介绍一些具有代表性的处于临床和临床前研究阶段的ERK抑制剂。

     

    Abstract: Extracellular signal-regulated kinase (ERK) is a kind of serine/threonine protein kinase. As a key downstream protein in RAS-RAF-MEK-ERK signaling pathway, its abnormal activation plays an important role in the development of tumors. Selective ERK1/2 inhibitors can block ERK signaling pathway while overcoming drug resistance caused by upstream target mutation. In this paper, the components of MAPK signaling pathway, the structure and functions of ERK and the role of ERK signaling pathway in tumor development are summarized, and some representative ERK inhibitors in clinical or preclinical studies are emphasized.

     

/

返回文章
返回